RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan
The efficacy and safety of Iosartan and valsartan were evaluated in a multicenter , double-blind , r and omized trial in patients with mild to moderate essential hypertension .  Blood pressure responses to once-daily treatment with either losartan 50 mg ( n = 93 ) or valsartan 80 mg ( n = 94 ) for 6 weeks were assessed through measurements taken in the clinic and by 24-hour ambulatory blood pressure monitoring ( ABPM ) . Both drugs significantly reduced clinic sitting systolic ( SiSBP ) and diastolic blood pressure ( SiDBP ) at 2 , 4 , and 6 weeks . Maximum reductions from baseline in SiSBP and SiDBP on 24hour ABPM were also significant with the two treatments . The reduction in blood pressure was more consistent across patients in the losartan group , as indicated by a numerically smaller variability in change from baseline on all ABPM measures , which achieved significance at peak ( P = .017 ) and during the day ( P = .002 ) . In addition , the numerically larger smoothness index with losartan suggested a more homogeneous antihypertensive effect throughout the 24-hour dosing interval . The anti hypertensive response rate was 54 % with losartan and 46 % with valsartan . Three days after discontinuation of therapy , SiDBP remained below baseline in 73 % of losartan and 63 % of valsartan patients . Both agents were generally well tolerated .  Losartan , but not valsartan , significantly decreased serum uric acid an average 0.4 mg/dL at week 6 . In conclusion , once-daily losartan 50 mg and valsartan 80 mg had similar anti hypertensive effects in patients with mild to moderate essential hypertension .  Losartan produced a more consistent blood pressure-lowering response and significantly lowered uric acid , suggesting potentially meaningful differences between these two A II receptor antagonists
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .